Seroba Life Sciences
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Seroba Life Sciences.
Key people at Seroba Life Sciences.
Seroba Life Sciences is a leading European venture capital firm specializing in early-stage investments in biotechnology and medical technology (medtech) companies. Headquartered in Dublin with offices in Paris and Milan, Seroba focuses primarily on Western Europe and selectively on North America. Its mission is to back cutting-edge innovations that transform patient treatment and address unmet medical needs. The firm has invested in over thirty life sciences companies, helping bring new medical devices and therapeutics to market. Seroba typically invests at seed and Series A stages, with initial ticket sizes ranging from €5 million to €10 million, partnering closely with entrepreneurs to build businesses around extraordinary science[1][2][3].
Founded in 2002, Seroba Life Sciences was established to capitalize on Europe’s strong scientific base and to foster innovation in biotech and healthcare. The firm has evolved to manage multiple funds and build a diversified portfolio across various indications in life sciences. Key partners include Alan O’Connell, Andrew Duignan, Bruno Montanari, and Catello Somma, who bring deep investment and industry expertise. Over time, Seroba has expanded its geographic reach and refined its focus on early-stage ventures with strong scientific foundations and breakthrough potential[1][3][5].
Seroba rides the global trend of increasing investment in life sciences innovation, particularly in biotech and medtech, where breakthroughs can significantly improve patient outcomes. Europe’s strong scientific research base combined with growing venture capital interest creates a favorable environment for Seroba’s model. The firm’s timing is critical as healthcare innovation accelerates, driven by advances in gene therapy, medical devices, and digital health. By backing early-stage companies, Seroba helps bridge the gap between scientific discovery and commercial success, influencing the broader ecosystem by fostering entrepreneurship and translating science into viable therapies and technologies[1][6].
Looking ahead, Seroba is well-positioned to continue capitalizing on the expanding biotech and medtech sectors, especially as personalized medicine, gene therapies, and advanced medical devices gain momentum. Trends such as digital health integration and precision therapeutics will likely shape its investment focus. Seroba’s influence is expected to grow as it supports more startups through critical early stages, helping Europe maintain and enhance its leadership in life sciences innovation. The firm’s commitment to value creation through science-driven ventures suggests a future of sustained impact on healthcare and patient treatment paradigms[1][2][6].
Key people at Seroba Life Sciences.
